References
- Barbey JT, Lazzara R, Zipes DP. (2002). Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 7:65–76.
- Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102.
- Darpö B. (2007). Detection and reporting of drug-induced proarrhythmias: room for improvement. Europace 9 Suppl 4:iv23–iv36.
- Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, Goldhaber SZ, King CR, Giri T, McLeod HL, Glynn RJ, Gage BF. (2010). Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 8:95–100.
- FitzGerald GA. (2002). Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 89:26D–32D.
- Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H. (2001). Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23:1603–1614.
- Johnson DE, Smith DA, Park BK. (2009). Pharmacogenomics and adverse drug reactions; Prospective screening for risk identification. Curr Opin Drug Discov Devel 12:27–30.
- Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, Rodrigo L, Balanzo J, Bajador E, Almela P, Navarro JM, Carballo F, Castro M, Quintero E; Investigators of the Asociación Española de Gastroenterología (AEG). (2005). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 100:1685–1693.
- MacFarlane RJ, Gelmon KA. (2011). Lapatinib for breast cancer: A review of the current literature. Expert Opin Drug Saf 10:109–121.
- McClain MR, Palomaki GE, Piper M, Haddow JE. (2008). A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med 10:89–98.
- Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. (2004). Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 329:15–19.
- Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. (2008). High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 46:1111–1118.
- Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. (2008). The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22:2025–2033.
- Scott MG. (2010). When do new biomarkers make economic sense? Scand J Clin Lab Invest Suppl 242:90–95.